GLPBio

Immunology/Inflammation

Read More about this category

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

Research Areas

Products Related to Immunology/Inflammation(4922)

  • GC72284 structure
    GC72284M-TriDAP
    CAS: 60230-21-9

    M-TriDAP (N-아세틸 트립토판-L-Ala-감마-D-Glu-meso-di 아미노경산) 은 NOD1/2 흥분제와 생체활성 펩타이드의 일종이다.

  • GC72306 structure
    GC72306Lib2-1
    CAS: 2983116-47-6
    Purity: >99.00%

    Lib2-1 대환펩타이드는 IL-17C/IL-17RE 상호작용 억제제다.

  • GC72319 structure
    GC72319Atrosab
    CAS: 1365659-05-7
    Purity: >96.00%

    Atrosab는 IgG1 옹색성 항TNFR1 항체의 일종이다.

  • GC72320 structure
    GC72320Temtokibart
    CAS: 2639874-57-8
    Purity: >99.00%

    Temtokibart는 IL22RA1을 대상으로 하는 휴머노이드 IgG1 람다 2 항체입니다.

  • GC72324 structure
    GC72324Dazukibart
    CAS: 2639474-65-8
    Purity: >99.00%

    Dazukibart은 mouse-derived, 서였 IgG1 κ 항체 인터페론 베 타 1 (IFNB1)을 겨냥하고 있다.

  • GC72326 structure
    GC72326Riliprubart
    CAS: 2756228-76-7
    Purity: >99.00%

    Riliprubart (SAR445088) 는 고전적인 보체 시스템의 근단 부분의 활성화 C1s를 억제하는 항C1s 인적 자원화 단일 클론 항체이다.

  • GC72327 structure
    GC72327Stapokibart
    CAS: 2734715-10-5
    Purity: >96.00%

    Stapokibart (CM310) 는 IL-4Rα를 표적으로 하는 인수화 단클론 항체로, 세포인자 IL-4와 IL-13과 그 공유체인 아기 IL-4Rα 간의 상호작용을 효과적으로 차단한다.

  • GC72340 structure
    GC72340Enokizumab
    CAS: 909875-08-7
    Purity: >99.00%

    Enokizumab (MEDI-528) 는 백혈구 매개체 (IL) -9에 대한 단일 클론 항체입니다.

  • GC72345 structure
    GC72345Tildrakizumab
    CAS: 1326244-10-3
    Purity: >95.00%

    Tildrakizumab (SCH 900222) 는 IL-23 (p19 아기) 단일 클론 항체에 대한 인적 항체입니다.

  • GC72352 structure
    GC72352Fontolizumab
    CAS: 326859-36-3
    Purity: >97.00%

    Fontolizumab (HuZAF) 는 휴먼 소스 단일 클론 항 IFN-감마 항체입니다.

  • GC72354 structure
    GC72354Lampalizumab
    CAS: 1278466-20-8
    Purity: >99.00%

    Lampalizumab (RG 7417)은 대체 보완 경로의 보완 인자 D를 목표로 하는 인간화 단일 클론 항체이다.

  • GC72358 structure
    GC72358Perakizumab
    CAS: 89957-37-9
    Purity: >99.00%

    Perakizumab (RG4934)는 서였 IgG1 κ IL-17A에 대한 단일 클론 항체 (Interleukin 관련)이다.

  • GC72359 structure
    GC72359Quilizumab
    CAS: 1228538-47-3
    Purity: >96.00%

    Quilizumab (항인 NGcGM3 재조합 항체) 는 일종의 인원화 IgG1 단일 클론 항체이다.

  • GC72363 structure
    GC72363Timolumab
    CAS: 1073538-99-4
    Purity: >98.00%

    Timolumab (BTT1023), VAP-1을 특이적으로 결합한 재조합 전인단 클론 항체.

  • GC72365 structure
    GC72365Visilizumab
    CAS: 219716-33-3
    Purity: >98.00%

    Visilizumab (항인 CD3E 재조합 항체) 는 인간화된 저Fc 수용체가 결합된 항CD3 단일클론 IgG2 항체이다.

  • GC72367 structure
    GC72367Vunakizumab
    CAS: 1792181-33-9
    Purity: 95.00%

    Vunakizumab (항인 IL17A 재조합 항체) 는 IL-17A를 표적으로 IL-17 수용체와의 상호작용을 억제하는 재조합 인간 IgG 단일 클론 항체이다.

  • GC72378 structure
    GC72378Neihulizumab
    CAS: 2158362-38-8
    Purity: >98.00%

    Neihulizumab (ALTB-168) 는 면역검사점 격동항체로 사람 CD162 (PSGL-1) 와 결합하여 활성화 T세포가 하향조정된다.

  • GC72380 structure
    GC72380Vobarilizumab
    CAS: 1628814-88-9
    Purity: >97.00%

    Vobarilizumab (ALX-0061) 는 IL-6R 단일 클론 저항 항체(mAb) (Kd: 0.19 pM)입니다.

  • GC72381 structure
    GC72381Sonelokimab
    CAS: 1414386-05-2
    Purity: >99.00%

    Sonelokimab (ALX 0761; M 1095) 는 단가 낙타과 동물에서 파생된 나노체로 구성된 3가 나노체로 인백혈구개소(IL)-17A, IL-17F 및 인혈청백단백질 VHH에 특이성을 가지고 있다.

  • GC72390 structure
    GC72390Anrukinzumab
    CAS: 910649-32-0
    Purity: >98.00%

    Anrukinzumab (IMA-638) 는 IL-13 단일 클론 저항체에 대한 인적 자원화입니다.

  • GC72391 structure
    GC72391Avdoralimab
    CAS: 2226393-85-5
    Purity: >95.00%

    Avdoralimab (IPH 5401) 는 C5a와의 결합을 막는 표적 보체인 C5a 수용체 1 (C5aR1) 인 전인IgG 단일 클론 항체이다.

  • GC72396 structure
    GC72396Cendakimab
    CAS: 2151032-62-9
    Purity: >99.00%

    Cendakimab (RPC4046; ABT 308; CC-93538)는 IL-13 분자에 대한 선택적 인간화 재조합 단일 클론 항체입니다.

  • GC72397 structure
    GC72397Ziltivekimab
    CAS: 2226654-05-1
    Purity: >99.00%

    Ziltivekimab (COR-001) 는 혈청 CRP를 낮추는 데 효과적인 사람 항 IL-6 단일 클론 항체입니다.

  • GC72415 structure
    GC72415Goflikicept
    CAS: 2416984-26-2
    Purity: >98.00%

    Goflikicept (RPH 104) 는 순환 중인 IL-1 베타와 IL-1 알파를 선택적으로 결합하여 불활성화시키는 교잡 단백질입니다.